Summary: “Dr. [Rachel] Yehuda’s work marks the first time that the VA has gone on record supporting research into MDMA, which remains a Schedule 1 drug,” explains Marc Gunther. Dr. Yehuda and her team plan to conduct a MAPS-sponsored Phase 2 controlled comparative study on the effectiveness of MDMA-assisted therapy in U.S. Veterans with chronic PTSD at the VA, pending DEA approval.
Originally appearing here.